<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Minimum recommended initial assessment and monitoring recommendations for patients with nonneuronopathic Gaucher disease</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Minimum recommended initial assessment and monitoring recommendations for patients with nonneuronopathic Gaucher disease</h1>
<div class="graphic"><div class="figure"><div class="ttl">Minimum recommended initial assessment and monitoring recommendations for patients with nonneuronopathic Gaucher disease</div><div class="cntnt"><table cellspacing="0"><colgroup span="3" width="33%"></colgroup> <tbody> <tr> <td class="subtitle1" rowspan="2">Initial assessment and ongoing monitoring</td> <td class="subtitle1" colspan="2">Frequency*</td> </tr> <tr> <td class="subtitle2">Not receiving ERT</td> <td class="subtitle2">Receiving ERT, has not achieved goals</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Physical examination</td> </tr> <tr> <td> </td> <td>Every 6 months</td> <td>Every 6 to 12 months</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Blood tests</td> </tr> <tr> <td class="indent1">Hemoglobin</td> <td>Every 12 months</td> <td>Every 3 months</td> </tr> <tr> <td class="indent1">Platelets</td> <td>Every 12 months</td> <td>Every 3 months</td> </tr> <tr> <td class="indent1">Chitotriosidase, PARC/CCL18, HDL</td> <td>Every 12 months</td> <td>Every 3 months</td> </tr> <tr> <td class="indent1">Beta-glucosidase and mutation analysis</td> <td> </td> <td> </td> </tr> <tr> <td class="indent1">Antibody sample<sup>¶</sup></td> <td>Not necessary</td> <td>Optional sample after 6 months of therapy</td> </tr> <tr> <td class="indent1">Serum immunoelectrophoresis<sup>Δ</sup></td> <td>Every 12 to 24 months in patients &gt;50 years</td> <td>Every 12 to 24 months in patients &gt;50 years</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Radiographs</td> </tr> <tr> <td class="subtitle3_left" colspan="3">Visceral</td> </tr> <tr> <td class="indent2">Spleen volume (MRI or US)</td> <td>Every 12 to 24 months</td> <td>Every 12 months</td> </tr> <tr> <td class="indent2">Liver volume (MRI or US)</td> <td>Every 12 to 24 months</td> <td>Every 12 months</td> </tr> <tr> <td class="subtitle3_left" colspan="3">Skeletal</td> </tr> <tr> <td class="indent1" colspan="3">MRI</td> </tr> <tr> <td class="indent2">Spine (sagittal T1-weighted)<sup>Δ</sup></td> <td>Every 24 months, or less frequently if consistently normal</td> <td>Every 12 months</td> </tr> <tr> <td class="indent2">Femora (coronal T1- and T2-weighted)</td> <td>Every 24 months, or less frequently if consistently normal (T1- and T2-weighted)</td> <td>Every 12 month (T1- and T2-weighted)</td> </tr> <tr> <td class="indent1" colspan="3">Plain radiographs<sup>◊</sup></td> </tr> <tr> <td class="indent2">Children: Pelvis, long bones, spine<sup>§</sup></td> <td>Every 12 to 24 months</td> <td>Every 12 months</td> </tr> <tr> <td class="indent2">Adult: Lateral spine; AP of entire femora<sup>¥</sup></td> <td>Every 12 to 24 months</td> <td>Every 12 months</td> </tr> <tr> <td class="indent2">DXA spine and hips</td> <td>Every 12 to 24 months in adults</td> <td>Every 12 months</td> </tr> <tr> <td class="subtitle3_left" colspan="3">Cardiopulmonary</td> </tr> <tr> <td class="indent1" colspan="3">Children:</td> </tr> <tr> <td class="indent2">Forced vital capacity</td> <td rowspan="5">Repeat if abnormal at baseline or if symptoms develop</td> <td rowspan="5">Repeat if abnormal at baseline or if symptoms develop</td> </tr> <tr> <td class="indent2">Peak expiratory flow rate</td> </tr> <tr> <td class="indent2">High-resolution chest computed tomography</td> </tr> <tr> <td class="indent2">Echocardiography</td> </tr> <tr> <td class="indent2">Electrocardiogram</td> </tr> <tr> <td class="indent1" colspan="3">Adults (&gt;18 years):</td> </tr> <tr> <td class="indent2">Electrocardiogram</td> <td rowspan="3"> <p>Every 12 to 24 months for those with borderline or above normal pulmonary pressures at baseline</p> Consider repeating every 2 to 3 years if baseline is normal</td> <td rowspan="3">Annual evaluation if signs/symptoms of cardiopulmonary disease are present</td> </tr> <tr> <td class="indent2">Chest radiograph</td> </tr> <tr> <td class="indent2">Doppler echocardiogram (right ventricular systolic pressure)</td> </tr> <tr> <td class="subtitle3_left" colspan="3">Other</td> </tr> <tr> <td class="indent2">Pain</td> <td>Every 12 months</td> <td>Every 6 to 12 months</td> </tr> <tr> <td class="indent2">Quality of life</td> <td>Every 12 months</td> <td>Every 12 months</td> </tr> <tr> <td class="indent2">Validated disease severity score</td> <td>Every 12 months</td> <td>Every 12 months</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Additional tests<sup>‡</sup></td> </tr> <tr> <td class="indent1" colspan="3">White blood count, prothrombin time, activated partial thromboplastin time, iron, iron-binding capacity, ferritin, vitamin B12, aspartate aminotransferase, and/or alanine aminotransferase; alkaline phosphatase; calcium, phosphorous, albumin, total protein, total and direct bilirubin; hepatitis profile, serum immunoelectrophoresis</td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>ERT: enzyme replacement therapy; PARC/CCL18: pulmonary and activation-regulated chemokine/chemokine (C-C motif) ligand 18; HDL: high-density lipoprotein; MRI: magnetic resonance imaging; US: ultrasonography; DXA: dual-energy x-ray absorptiometry.</p>
<p>* The entire assessment should be performed at baseline and every 12 to 24 months in patients who are receiving ERT and have achieved therapeutic goals. DXA should be performed every 24 months in these patients. The entire assessment also should be performed at the time of dose change or the development of a significant complication.</p>
<p>¶ To be stored and tested only if clinically indicated.</p>
<p>Δ Only in children.</p>
<p>◊ Sites not included here should be evaluated if symptoms develop.</p>
<p>§ Plain radiographs of the spine only when patient is symptomatic (eg, back pain), disease is severe, there is poor growth, or kyphosis.</p>
<p>¥ Optional in absence of new symptoms or evidence of disease progression.</p>
	
	‡ Additional tests to be considered and followed appropriately depending upon patient's age and clinical status.</div><div class="graphic_reference">Data from:
	<ol>
<li>Grabowski GA, Andria G, Baldellou A, et al. Pediatric nonneuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements. Eur J Pediatr 2004; 163:58.</li>
<li>Baldellou A, Andria G, Campbell PE, et al. Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoring. Eur J Pediatr 2004; 163:67.</li>
<li>Charrow J, Andersson HC, Kaplan P, et al. Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations. J Pediatr 2004; 144:112.</li>
<li>Weinreb NJ, Aggio MC, Andersson HC, et al. Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients. Semin Hematol 2004; 41:15.</li>
<li>Rosenbloom BE, Weinreb NJ, Zimran A, et al. Gaucher disease and cancer incidence: a study from the Gaucher Registry. Blood 2005; 105:4569.</li>
</ol></div><div id="graphicVersion">Graphic 57808 Version 13.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
